Abstract 6079
Background
This study focuses on epidemiology of IFD before and after allo-HSCT in children and adults with Hodgkin’s lymphoma (HL).
Methods
Single center prospective observational study included 86 patients with classical r/r HL who received allo-HSCT from 2002 to 2018. The median age was 27 (13-49) y.o., children (<18 yo) – 13% (n = 11). Allo-HSCT from MUD was performed in 45,4% (n = 39), MRD – 24,4% (n = 21), MMUD – 15,1% (n = 13), haplo – 15,1% (n = 13), with RIC (100%) and predominantly PTCY-based GvHD prophylaxis (71%). Primary antifungal prophylaxis was flu in 85%, secondary – vori (100%). EORTC/MSG 2008 criteria for diagnosis and response to therapy were used. Median follow-up time was 12 months [1-71].
Results
Incidence of IFD before allo-HSCT was 12,8% (n = 11). Antifungal therapy before allo-HSCT was used in 81,8% pts with median duration – 2 months. Complete response to antifungal therapy was in 45,4% pts, partial response or stabilization – 36,4%, and 18,2% pts had an “active IFD”. Cumulative incidence of relapse or progression of IA after allo-HSCT was 18,2% with the median 49 day [19-79] after HSCT, which were successfully treated with vori in post HSCT period. Incidence of IFD after allo-HSCT for naïve patients was 17,6% (n = 13/74). Etiology of IFD after allo-HSCT was IA – 69%, invasive candidiasis – 15%, mucormycosis – 8% and 8% combined IFD caused by Asp. fumigatus + Rhizopus stolonifer. The median day of onset of IFD after allo-HSCT was day+ 114 [1-489]. Antifungal therapy was used in all patients: vori – 59%, mica– 17%, posa – 8%, L-AmB – 8% and combination L-AmB with caspo – 8%. Overall survival (OS) at 12 weeks from the diagnosis of IFD after allo-HSCT was 80%. The 2-year OS in children and adult with HL after allo-HSCT was 73,3%. Development of IFD after allo-HSCT do not decrease the 2-year OS rate (69,2% vs 74%, p = 0,77, figure 1a). The impact of prior IFD on 2-year OS in allo-HSCT recipients was not statistically significant in all group (63,6% vs 74,7%, p = 0,47, figure 1b), and separately in children and adults.
Conclusions
Incidence of IFD before allo-HSCT was 12,8%. Incidence of IFD after allo-HSCT was 17,6%. Despite the high incidence IFD before or after allo-HSCT didn’t influence the outcome in children and adults with Hodgkin lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4125 - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone
Presenter: Ramon Mohanlal
Session: Poster Display session 1
Resources:
Abstract
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract